Alzheimer’s & Dementia

As Big Pharma continues to flail away on the Alzheimer’s front, new research increasingly turns toward identifying lifestyle changes that can lower the risk of falling prey to the disease.

Can certain personality traits protect us from cognitive dysfunction as we grow old? New research holds out some hope, but I have my doubts.

Could regular daytime napping be a precursor to dementia — or even a sign that the disease has already taken hold? A new take on what has generally been considered a salutary practice creates some concerns, despite its caveats. I’m going to try not to lose any sleep over it.

Biogen, the maker of the controversial Alzheimer’s drug Aduhelm, last week released the long-awaited results of two clinical trials — which promptly raised more questions than they answered.

Concerned about my septuagenarian friend’s sudden memory lapse, I was comforted by new research suggesting that a little forgetfulness may not be a bad thing.

While the Medicare set awaits a final decision on coverage for Biogen’s controversial Alzheimer’s drug, a new study suggests seniors may get the same benefits from regular exercise. Both approaches, however, raise more questions than they answer.

The approval of a controversial Alzheimer’s drug has triggered a major increase in monthly Medicare premiums — and fresh concerns about the program’s solvency. I’m hoping it also sparks some new thinking about prescription-drug pricing.

While Alzheimer’s patients wait to see if Biogen’s new drug will someday prove effective — and affordable — researchers continue to make a case for the healing powers of meditation.

Raging wildfires and other sources of airborne pollution are threatening more than our respiratory and circulatory systems. New research is strengthening the link between air quality and dementia.

The controversy surrounding the FDA’s approval of the first new Alzheimer’s drug in nearly two decades will do little to temper demand by desperate patients and their caregivers. It may also exacerbate racial disparities among those vying for the treatment.

Cases of the debilitating neurological disease have been surging in recent years and some researchers suggest COVID-19 may accelerate the trend.